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Background: Angiotensin-converting enzyme (ACE) inhibitors-related cough had been reported to con-
tribute for discontinuation of ACE inhibitors therapy. The role of ACE I/D and bradykinin B2 receptor T/C
genes in ACE inhibitors-related cough is still unclear.
Objectives: To determine ACE I/D and bradykinin B2 receptor T/C genes polymorphisms in patients with
ACE-inhibitors-related cough.
Subjects and methods: An analytical study with cross-sectional design was conducted at Saiful Anwar
General Hospital from June 2013 to September 2014. We used the polymerase chain reaction to genotype
ACE I/D and bradykinin B2 receptor T/C genes. Data on both ACE I/D and bradykinin B2 receptor T/C genes
polymorphisms in cough and non cough group of hypertensive patients treated with ACE inhibitors in
our Hospital during the period were analyzed using multiple logistic regression. Moreover, a meta-
analysis was performed to summarize findings from other regions.
Results: A total of 18 patients with cough (21%) and 67 patients without cough (79%) of hypertensive
patients treated with ACE inhibitors from our Hospital during the period were analyzed for this study.
In our population, no correlation was observed between ACE inhibitors-related cough and both ACE I/D
(p = 0.560) and bradykinin B2 receptor T/C (p = 0.475) genes polymorphism. However, our meta-analysis
of five studies consisting of 267 patients with cough and 346 patients without cough revealed that higher
risk of ACE inhibitors-related cough was 1.82-fold associated with T allele of bradykinin B2 receptor T/C
gene polymorphism (p = 0.0310).
Conclusions: While the evidence in our meta-analysis suggests strong role for bradykinin gene polymor-
phism in ACE inhibitors-related cough, however, in our population, we did not find any association.
 2018 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Angiotensin-converting enzyme (ACE) inhibitors have been
widely used as gold standard and established as corner-stones
for the management of hypertension [1,2]. However, it has been
reported that ACE inhibitors therapy are accompanied by several
side-effects [3], and the most often reported ACE inhibitors side-
effect is ACE inhibitors-related cough [4]. First reported in 1985
[5], until now, the incidence of ACE inhibitors-related cough is vari-able, ranging from 0.7 to 35% [4,6–10], and has been associated
with the reasons for patients to discontinue the treatment of
hypertension. The incidence of ACE inhibitors discontinuation
due to cough is about 4–50% of all patients with ACE inhibitors-
related cough [4,11–13]. It has been known that hypertension is
the most crucial risk factor for stroke [14], coronary heart disease
(CHD) [15], heart failure (HF) [16], and end-stage renal disease
(ESRD) [17,18]. Therefore, the cessation of hypertensive treatment
is very detrimental for the patients.
The incidence data [4,6–10] suggested that ACE inhibitors-
related cough only occurred in some patients. This means that
genetic factors may play an important role for the development of
ACE inhibitors-related cough. Although the etiology of ACE
inhibitors-related cough remains unclear [9], however, theoretically,
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genesis of ACE inhibitors-related cough [4] and these levels are
proven to be influenced by genes polymorphism. Abbas et al.
[19] reported that DD genotypes of ACE insertion/deletion (I/D) gene
polymorphism on chromosome 17q23 were associated with higher
ACE serum levels, and higher bradykinin activity was observed in T
allele of bradykinin B2 receptor  58 T/C gene polymorphism [20].
Since 1990 s, some studies had reported the correlation between
genes [ACE I/D and bradykinin B 2 receptor T/C] polymorphism
and ACE inhibitors-related cough in different populations
[20–29]. However, in Indonesia, until now, no study has been
conducted to evaluate these associations.
Our present study aimed to evaluate the association between
ACE inhibitors-related cough and the polymorphisms of both ACE
I/D and bradykinin B2 receptor T/C genes in our Hospital. Moreover,
due to the reports concerning the association between both ACE I/D
and bradykinin B2 receptor T/C genes polymorphism and the risk of
ACE inhibitor-related cough remained conflicting [20–29], we also
performed a meta-analysis to conclude the association.2. Subjects and methods
2.1. Study designs and patients
During the period (June 2013–September 2014), an analytical
study with cross-sectional design was conducted in Saiful Anwar
General Hospital, Malang, Indonesia to assess the association
between ACE inhibitors-related cough and [ACE I/D and bradykinin
B2 receptor T/C] genes polymorphisms in hypertensive patients
treated with ACE inhibitors. The target population was all hyper-
tensive patients treated with ACE inhibitors in our Hospital during
June 2013–September 2014. We used total sampling method. The
inclusion criteria were all essential hypertensive subjects for more
than two years who had been given ACE inhibitors at a daily dose
for eight weeks or more. Subjects with the following condition
were excluded, i.e.: (1) patients with any secondary cause of
hypertension; (2) patients with a history of recent respiratory
infection, other respiratory diseases, or pulmonary congestion;
(3) patients with productive coughing or with chest X-ray prob-
lems; (4) patients who disagree to give blood for the study. The
diagnosis of patients with ACE inhibitors-related cough was
adapted from previous studies [20,24,28–30]. Subjects who com-
plained of dry cough, and their symptoms had disappeared soon
after withdrawal of the ACE inhibitors [24,28,29] and or after tak-
ing medicine were categorized [20,30] as cough group. While,
patients with no complaint of cough were classified as non cough
group. We collected blood samples from the peripheral vein. Then,
they were put in EDTA-coated tubes and kept cold. Within 72 h,
QIAamp kit (QiaGen, Tokyo, Japan) was used to extract the DNA
from leukocytes according to the standard protocol [28,29]. This
study was approved by Ethical Committee of Brawijaya University,
Malang, Indonesia, and carried out in accordance with The Code of
Ethics of the World Medical Association (Declaration of Helsinki)
for experiments in humans. All patients had signed written
informed consent prior to the study.2.2. ACE I/D genotype determination
The ACE I/D gene polymorphism was identified by polymerase
chain reaction (PCR) as described by previous studies [20,24,
28,29] with some modifications. A set of primers (forward 50-GCC
CTGCAGGTGTCTGCAGCATGT-30 and reverse 50-GGATGGCTCTCCCC
GCCTTGTCTC-30) was designed to cover the polymorphic region
in intron of the ACE gene. A 20 mL of total reaction volume con-
tained 2 mL of genomic DNA, 2 mL of each primer, 4 mL of ddH2O,and 10 mL PCR mixture. Amplification was performed using a ther-
mal cycler (Perkin Elmer 2400, Boston, USA). DNA was amplified
for 34 cycles and each cycle consisted of pre-denaturation at
95 C for five minutes, denaturation at 96 C for 45 s, annealing
at 60.3 C for 45 s, extension at 72 C for 45 s, and post-extension
at 72 C for 10 min. We used electrophoresis on a 2% agarose gel
(Hoeffer, Holliston, USA) to separate PCR products.
2.3. Bradykinin B2 receptor T/C genotype determination
A 20 mL of total reaction volume contained 1 mL of genomic DNA,
0.5 mL of each primer (forward 5-GCAGAGCTCAGCTGGAGGCG-3
and reverse 5-CCTCCTCGGAGCCCAGAAG-3), 8 mL of ddH2O, and
10 mL PCR mixture with each primer concentration was 10 pmol.
DNA was amplified for 35 cycles, each cycle consisted of pre-
denaturation at 95 C for five minutes, denaturation at 95 C for
one minute, annealing at 63 C for 30 s, extension at 72 C for
one minute, and post-extension at 72 C for 10 min. The PCR prod-
ucts were separated by electrophoresis on a 1% agarose gel. To
determine bradykinin B2 receptor gene polymorphism, the PCR
products were electrophoresed using single-strand conformation
polymorphism (SSCP) method. A 5 mL of the PCR product was
diluted with 5 mL formamide, denatured at 95 C for 10 min, and
subjected to SSCP analysis in a 18.5% polyacrylamide (2 TBE)
gel. Electrophoresis was conducted in 2 TBE buffer at room tem-
perature and 150 V for 210 min, and the gels were then silver-
stained. Some samples representative of each genotype detected
by SSCP were sequenced by fluorescent cycle sequencing to con-
firm the presence of T or C at nucleotide position-58 upstream of
the putative transcription start site. The method was adapted from
the previous studies [20,24,28,29].
2.4. Statistical analysis
The association between ACE inhibitors-related cough and [ACE
I/D and bradykinin B2 receptor T/C] genes polymorphisms was ana-
lyzed using multiple logistic regression. All significance tests were
two tailed and P-value of <0.05 was considered statistically signif-
icant. All analysis was performed using the Statistical Package of
Social Sciences 17.0 software (SPSS Inc., Chicago, IL).
2.5. Meta-analysis
A meta-analysis was also employed to assess the association
between ACE inhibitors-related cough and [ACE I/D and bradykinin
B2 receptor T/C] genes polymorphisms. The method of meta-
analysis was adapted from our previous studies [31–37]. The inclu-
sion criteria for meta-analysis were: (1) retrospective studies; (2)
prospective studies; (3) cross-sectional studies; (4) randomized-
controlled trials (RCTs); (5) controlled before-and-after studies;
(6) cross-over studies; (7) investigating the association between
ACE inhibitors-related cough and [ACE I/D and bradykinin B2 recep-
tor T/C] genes polymorphisms; and (8) providing sufficient data for
calculating odd ratio (OR) and 95% confidence interval (CI). Briefly,
articles concerning the association between ACE inhibitors-related
cough and [ACE I/D and bradykinin B2 receptor T/C] genes polymor-
phisms were comprehensively searched on PubMed and Embase
up to January 15th, 2018. For searching strategy, the combination
of the following key words was used: (ACE inhibitors-related
cough OR angiotensin-converting enzyme inhibitors-related
cough) AND (ACE I/D gene polymorphism or angiotensin-
converting enzyme I/D gene polymorphism) OR (bradykinin B2 recep-
tor T/C gene polymorphism). For each study, information regarding:
(1) first author name; (2) publication year; (3) country of origin;
(4) ethnicity; and (5) sample sizes of cough and non cough group
were extracted. The association between ACE inhibitors-related
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phisms was determined by calculating pooled OR 95% CIs. The sig-
nificance of pooled ORs was estimated by Z-tests (p < 0.05 was
considered statistically significant). A Q-test was employed to eval-
uate whether heterogeneity existed. A random effects model was
used to calculate the OR 95% CI if heterogeneity existed (p < 0.10),
otherwise a fixed effects model was used. To assess publication
bias, an Egger’s test was used (p < 0.05 was considered statistically
significant). We used a Comprehensive Meta-analysis 2.0 software
(CMA, New Jersey, USA) to analyze the data.
3. Results
During this period, a total of 1327 patients were selected for the
study. Of these, 648 patients (48.8%) were excluded because of sec-
ondary hypertension, 251 patients (18.91%) were excluded because
of pneumonia, 67 patients (5.05%) were excluded because of pul-
monary congestion, 13 patients (0.98%) were excluded because of
lung tumor, and 263 patients (19.82%) were excluded because they
disagreed to join the study. Finally, 85 patients were included in
the study. A flowchart of the study is shown in Fig. 1.Fig. 1. Flowchart of the study. ACE, angiotensin-converting enzyme; ACEI,
angiotensin-converting enzyme inhibitor.
Table 1
Baseline characteristics and laboratory findings of the study.
No. Covariates Cough
1 Age (years; mean ± SD) 62.0 ± 1
2 Male (n[%]) 7 (38.9
3 Hypertension duration (months; mean ± SD) 97.0 ± 7
4 Systolic pressure (mmHg; mean ± SD) 150.0 ±
5 Diastolic pressure (mmHg; mean ± SD) 93.0 ± 9
6 Type of ACEi
Captopril (n[%]) 8(44.4)
Lisinopril (n[%]) 8(44.4)
Ramipril (n[%]) 2(11.1)
7 Urea (mg/dl; mean ± SD) 29.0 ± 8
8 Creatinine (mg/dl; mean ± SD) ± 0
9 Uric acid (mg/dl; mean ± SD) 6.0 ± 1.
10 Total cholesterol (mg/dl; mean ± SD) 211.0 ±
11 LDL (mg/dl; mean ± SD) 126.0 ±
12 HDL (mg/dl; mean ± SD) 51.0 ± 1
13 Triglyceride (mg/dl; mean ± SD) 178.0 ±
14 Fasting blood glucose (mg/dl; mean ± SD) 104.0 ±
15 Two-hour postprandial blood glucose (mg/dl; mean ± SD) 122.0 ±
Notes: ACE, angiotensin-converting enzyme; ACEi, angiotensin-converting enzyme in
lipoprotein; OR, odds ratio; CI, confidence interval.The incidence of cough and non cough groups in our study were
21% (18 cases) and 79% (67 cases), respectively. The average age of
the cough group was 62.0 (±10.25) years old with the average sys-
tolic blood pressure was 150.0 (±17.80 mmHg). Other parameters
of the patients such as duration of hypertension, type of ACE inhi-
bitors, and laboratory findings are presented in Table 1. Of those
baseline characteristics and laboratory findings, only duration of
hypertension and diastolic blood pressure were associated with
ACE inhibitors-related cough.
Table 2 shows the distributions of the genotypes frequencies of
the polymorphisms of ACE I/D and bradykinin B2 receptor T/C genes
in cough and non cough groups. Results of PCR product elec-
trophoresis for ACE I/D gene and results of SSCP for bradykinin
B2 receptor gene are described in Fig. 2. For ACE I/D, the genotype
frequencies were 38.9% for II, 44.4% for ID, 16.7% for DD in patients
with ACE inhibitors-related cough and 50.7% for II, 22.4% for ID,
and 26.9% for DD in subjects without cough. For bradykinin B2
receptor T/C, the genotype frequencies in patients with ACE
inhibitors-related cough were 44.4% for TT, 0% for TC, 55.6% for
CC, while in subjects without cough were 25.4% for TT, 9% for TC,
and 65.7% for CC. In our population, we found that both ACE I/D
(p = 0.560) and bradykinin B2 receptor T/C (p = 0.475) genes poly-
morphism were not associated with the risk of ACE inhibitors-
related cough.
In the meta-analysis; for ACE I/D gene polymorphism, a total of
546 patients with cough and 1232 patients without cough of ten
studies [21–29] including our study were analyzed. For bradykinin
B2 receptor T/C gene polymorphism, we included five studies
[20,24,28,29] including our study consisting of 267 patients with
cough and 346 patients without cough for meta-analysis. A flow-
chart concerning studies included in meta-analysis is described
in Fig. 3. Overall, the results showed no significant association
between ACE I/D gene polymorphism and ACE inhibitors-related
cough (Fig. 4). However, pooled data suggested that T allele of bra-
dykinin B2 receptor T/C gene polymorphism was associated with
increase the risk of ACE inhibitors-related cough (OR95%CI = 1.82
[1.06–3.13], p = 0.0310). A forest plot regarding the correlation
between ACE inhibitors-related cough and ACE I/D gene polymor-
phism is displayed in Fig. 4, while bradykinin B2 receptor T/C is
described in Fig. 5. A summary of the ORs and 95% CIs regarding
the correlation between ACE inhibitors-related cough and these
genes is shown in Table 3.(n = 18) Not cough (n = 67) p OR 95%CI
0.25 61.0 ± 9.57 0.268 1.06 0.96–1.17
) 22 (32.8) 0.419 0.41 0.05–3.55
9.00 70.0 ± 54.59 0.031 1.01 1.00–1.03
17.80 150.0 ± 16.46 0.063 0.93 0.87–1.00
.66 87.0 ± 10.85 0.025 1.13 1.02–1.25
0.133 0.40 0.12–1.32
27 (40.3)
33 (49.3)
7 (10.4)
.75 29.0 ± 11.63 0.252 1.07 0.96–1.19
.26 0.35 0.116 0.03 0.01–2.40
61 6.0 ± 2.31 0.654 0.88 0.52–1.51
47.28 175.0 ± 45.55 0.073 1.07 1.01–1.13
38.55 111.0 ± 33.12 0.054 0.94 0.89–1.00
1.29 47.0 ± 10.92 0.354 0.96 0.87–1.05
113.20 126.0 ± 57.50 0.756 1.00 0.99–1.01
24.98 96.0 ± 31.37 0.224 1.03 0.98–1.09
32.63 122.0 ± 43.29 0.345 0.98 0.94–1.02
hibitor; SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density
Table 2
Distributions of the genotypes and alleles frequencies in our study.
Genes polymorphism Cough (n = 18) Non cough (n = 67) p OR 95%CI
ACE I/D polymorphism II (n[%]) 7(38.9) 34 (50.7) 0.560 1.33 0.51–3.52
ID (n[%]) 8 (44.4) 15 (22.4)
DD (n[%]) 3 (16.7) 18 (26.9)
I (n[%]) 22 (61.1) 83 (61.9)
D (n[%]) 14 (38.9) 51 (38.1)
Bradykinin b2 receptor T/C polymorphism TT (n[%]) 8 (44.4) 17 (25.4) 0.475 0.74 0.32–1.71
TC (n[%]) 0 (0) 6 (9.0)
CC (n[%]) 10 (55.6) 44 (65.7)
T (n[%]) 16 (44.4) 40 (29.9)
C (n[%]) 20 (55.6) 94 (70.1)
Notes: ACE, angiotensin-converting enzyme; OR, odds ratio; CI, confidence interval.
Fig. 2. A). Results of PCR product electrophoresis for ACE I/D gene. The 599 bp band
shows the II genotypes (2, 5, 6, 8, 10, 11), 312 bp indicates DD genotypes (1,3,9,12),
two bands of 312 bp and 599 bp indicate ID genotype (4). The seventh row is a
1000 bp marker. B). Results of amplification of bradykinin B2 receptor T/C gene. C).
Results of SSCP for bradykinin B2 receptor T/C gene.
Fig. 3. Flowchart of studies selection in meta-analysis, with specification of
reasons.
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ACE inhibitors have been widely used for the management of
hypertension [2]. Dry cough is the most frequent reported ACE
inhibitors side-effects, and has been the most frequent reason for
patients to discontinue ACE inhibitors therapy [4,38]. The mecha-
nism of ACE inhibitors-related cough may involve several genes
such as ACE I/D and bradykinin B2 receptor T/C [4,39]. Our study
reported ACE I/D and bradykinin B2 receptor T/C genes polymor-
phism in subjects with ACE inhibitors-related cough.
In Indonesia, ACE I/D gene polymorphism studies had been
reported by Rasyid et al. [40] and Bawazier et al. [41]. However,
they did not correlate the gene with ACE inhibitors-related cough.
This is the first study in Indonesia regarding the correlationbetween ACE I/D and bradykinin B2 receptor T/C genes polymor-
phism with the risk of ACE inhibitor-related cough. The first study
regarding this association was conducted by Furuya et al. [21] in
Japan population. Basically, the concept of this study had similari-
ties with several studies regarding the correlation between the
genes and the risk of ACE inhibitors-related cough. In our popula-
tion, the incidence of ACE inhibitors-related cough was 21% of all
hypertensive patients treated with ACE inhibitors. This incidence
was in range as reported by several studies [4,6–10]. Moreover,
of the exclusion process, interestingly, our findings showed that
the incidence of secondary hypertension in our Hospital (48.8%)
was higher than that reported by several studies, ranging from 5
to 30% of all hypertensive patients [42–46]. This may be due to that
our Hospital is the referral center. Therefore, most patients in our
hospital have complicated clinical conditions, including secondary
hypertension-associated conditions. Perhaps, if this study was con-
ducted at all Hospitals in our area, the incidence of secondary
hypertension would not be as high as we reported.
The correlation between ACE inhibitors-related cough and ACE
I/D gene polymorphism has been widely reported in some coun-
tries. In our population, no correlation was observed between
ACE I/D gene polymorphism and ACE inhibitors-related cough. The-
oretically, ACE level is associated with ACE inhibitors-related
cough and this level is linked to ACE I/D gene polymorphism
[19,47]. However, our study failed to support this theory. Several
factors need to be evaluated to elucidate this correlation. Totally,
nine previous studies [21–29] had been conducted concerning
the association between ACE I/D gene polymorphism and the risk
of ACE inhibitors-related cough. However, of these studies, some
limitations were noted, such as no specific method to determine
Fig. 4. Forestplot the association between ACE I/D gene polymorphism and ACE inhibitors-related cough. A). I vs D; B). II vs ID + DD; C). ID vs II + DD.
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inhibitors-related cough were not included. In our study, these
limitations were eliminated. Furthermore, our meta-analysis found
that ACE I/D gene polymorphism was not associated with the risk of
ACE inhibitors-related cough. See Fig. 4. Our meta-analysis
extended the previous studies [48,49] revealed that, overall, ACE
I/D gene polymorphism was not correlated with the risk of ACE
inhibitors-related cough, although association was found in sub-
jects with age over 60 years old [50] and Asian population [48].
However, several studies included in their meta-analysis were
not found. In our meta-analysis, all studies were available, and
therefore our meta-analysis was more reliable than theirs.
Our results showed that bradykinin B2 receptor T/C gene poly-
morphism was not associated with the risk of ACE inhibitors-
related cough. Our results were consistent with Woo et al. [29]
and Zee et al. [24], but contrast with Mukae et al. [20] and Mukae
et al. [28]. Because of these differences, we performed a meta-
analysis to determine the actual association. Of five studies includ-
ing our study, the pooled data suggested that T allele of bradykinin
B2 receptor T/C gene polymorphism was correlated with 1.82-fold
increased risk of ACE inhibitors-related cough. The mechanism of
ACE inhibitors-related cough is still unclear. However, some litera-
tures reveal that the mechanism involves prostaglandins, bradyki-
nins, and tachykinins that accumulate in the upper respiratorytract and lung. Furthermore, they may activate kininase II activity
and stimulate unmyelinated aferen-C sensory nerve which is
responsible for producing the dry cough. Normally, these sub-
stances are degraded by ACE and cause suppression of kininase II
activity. Therefore, ACE inhibition is thought to cause decreased
metabolism of theses substances and play a crucial role for the
development of ACE inhibitors-related cough [4,9,27,50]. This
mechanism migh be a benchmark for our meta-analysis found that
bradykinin B2 receptor T/C gene polymorphism had a significant
association with the risk of ACE inhibitors-related cough.
Although our meta-analysis showed that bradykinin B2 receptor
T/C gene polymorphism was associated with the risk of ACE
inhibitors-related cough, however, because of small sample size,
it is not possible to use this covariate as the predictor for ACE
inhibitors-related cough. Nevertheless, since the genes were theo-
retically assumed to correlate with ACE inhibitor-related cough
and the reports remained inconclusive, further studies are required
to find the better outcome involving a larger sample size with
multiple ethnicities. Moreover, this study has the potency to
contribute in the development of better understanding about drugs
pharmacogenetic, and it is expected that, in the near future, this
study may help to improve the drugs design.
There were several limitations in the study. First, in this study
was not included data regarding the factors associated with ACE
Fig. 5. Forestplot the association between bradykinin B2 receptor T/C gene polymorphism and ACE inhibitors-related cough. A). T vs C; B). TT vs TC + CC; C). TC vs TT + CC.
Table 3
Summary of meta-analysis concerning the association between ACE I/D and bradykinin B2 receptor T/C genes polymorphism with ACE inhibitor-related cough.
Gene polymorphisms Alleles/genotypes Model OR 95%CI pE pH p
ACE I/D I vs D Random 1.10 0.84–1.43 0.3240 0.0080 0.4900
II vs ID + DD Random 1.17 0.81–1.69 0.4140 0.0370 0.4000
ID vs II + DD Random 0.86 0.68–1.08 0.2780 0.1220 0.1880
Bradykinin B2 receptor T/C T vs C Random 1.82 1.06–3.13 0.5440 0.0010 0.0310
TT vs TC + CC Random 2.21 1.04–4.66 0.7050 0.0080 0.0380
TC vs TT + CC Fixed 1.01 0.71–1.43 <0.0001 0.9000 0.9680
Notes: ACE, angiotensin-converting enzyme; OR, odds ratio; CI, confidence interval; pE, p Egger; pH, p Heterogeneity.
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and history of drug use. Second, false negative results could be
occurred in this study due to the small sample size. Third, our
results did not fully reflect the Indonesian population because
samples were recruited only from Saiful Anwar General Hospital.
Fourth, all of the studies included in our meta-analysis were
cross-sectional. Further meta-analysis including only RCT studies
are needed to get a better level of evidence.5. Conclusion
Our population data revealed that both ACE I/D and bradykinin
B2 receptor T/C genes polymorphism were not associated with the
risk of ACE inhibitors-related cough. However, our meta-analysis
found that T allele of bradykinin B2 receptor T/C genewas associated
with increased the risk of ACE inhibitors-related cough. Our results
may develop better understanding concerning the correlation
between these genes and the risk of ACE inhibitor-related cough.Conflict of interest
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